Scibase

SciBase announces exclusive distribution agreement with Equipmed for Australia and New Zealand

Pressmeddelande   •   Jun 20, 2013 04:00 CEST

SciBase, a Swedish company introducing a break-through product, Nevisense, for skin cancer detection, announced today that it has entered into an exclusive agreement with Equipmed to distribute Nevisense in Australia and New Zealand.

Equipmed is a successful distributor of equipment within dermatology in Australia and New Zealand, says Anders Lundqvist, CEO of SciBase. Equipmed has extensive knowledge and experience in the market for dermatological and skin care devices, and has been successful in bringing advanced new technologies to the market. Equipmed will distribute Nevisense, and also facilitate customer training and servicing throughout the Australian and New Zealand markets. The market for Nevisense is not the number of diagnosed malignant melanomas, it is the extensive screening done to detect them early in its most treatable state. Screening for malignant melanoma in Australia is by far the highest in the world, which makes Australia one of our most important markets, says Anders Lundqvist.

Australia has one of the highest per capita rates of skin cancer in the world, and malignant melanoma is one of the most fatal forms of cancer if not detected in time, says Stene Marshall, CEO of Equipmed. We are therefore very happy to introduce this product to the Australian market, as it has the potential to increase the accuracy in early detection of malignant melanoma and could save many lives. The Nevisense product has shown very convincing results in the pivotal study, which in fact is the largest study ever conducted with devices for melanoma detection.

Equipmed, with offices in Sydney, Melbourne, Brisbane and Perth as well as Auckland in New Zealand, is the leading independent distributor of devices in dermatology in the region.

The Cancer Council of Australia reports that over the past decades, the incidence of skin cancer has risen in Australia. From 1982 to 2007 melanoma diagnoses increased by around 50%, and is today the most common cancer in Australians aged 15-44. In 2009, more than 11,500 people in Australia were diagnosed with melanoma and in 2011, 1,544 people died due to melanoma.

About Equipmed
Equipmed’s aesthetic, cosmeceutical, dermatological and disinfection equipment uses the latest, cutting-edge technology. This is backed by expert training, marketing, support and service, designed to help customers deliver real results and build upon proven success. Equipmed has been a leading independent distributor of equipment for the cosmetic, dermatological, disinfection and cardiology industries since 1976.

About SciBase

Founded in 1998, SciBase is a Swedish medical technology company that has developed a unique diagnostic support tool for accurate detection of malignant melanoma. Following 20 years of academic research at Karolinska Institutet Stockholm, the ability of the Nevisense point-of-care device to accurately detect melanoma is now proven in the world’s largest prospective study of its kind.

For more information, please contact: Anders Lundqvist, CEO, SciBase AB, +46 732 06 98 08 Per Svedenhag, Director Clinical & Commercial Operations, SciBase AB, +46 732 06 98 01

Founded in 1998, SciBase is a Swedish medical technology company that has developed a unique diagnostic support tool for accurate detection of malignant melanoma. Following 20 years of academic research at Karolinska Institutet Stockholm, the ability of the Nevisense point-of-care device to accurately detect melanoma is now proven in the world’s largest prospective study of its kind.

For more information, please visit  www.scibase.se

Bifogade filer

PDF-dokument